AtaiBeckley Inc. is a clinical-stage biopharmaceutical company developing mental health treatments. The company's pipeline of novel therapies includes BPL-003 for treatment-resistant depression, VLS-01 for TRD and EMP-01 for social anxiety disorder. AtaiBeckley Inc., formerly known as Atai Beckley N.V., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $4.09M |
| Net Income (Most Recent Fiscal Year) | $-660.05M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 753.12 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 10.73 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -19019.44% |
| Return on Equity (Trailing 12 Months) | -89.79% |
| Return on Assets (Trailing 12 Months) | -63.58% |
| Current Ratio (Most Recent Fiscal Quarter) | -- |
| Quick Ratio (Most Recent Fiscal Quarter) | -- |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.69 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.08 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.57 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.23 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 368.17M |
| Free Float | 295.27M |
| Market Capitalization | $2.63B |
| Average Volume (Last 20 Days) | 21.86M |
| Beta (Past 60 Months) | 1.56 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 19.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 28.41% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |